CRIS Current Research Information System

IORIO, ALFONSO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.801
NA - Nord America 2.280
EU - Europa 935
SA - Sud America 139
AF - Africa 73
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 1
Totale 6.235
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.120
VN - Vietnam 991
BD - Bangladesh 522
CN - Cina 460
IT - Italia 402
SG - Singapore 342
GB - Regno Unito 179
HK - Hong Kong 104
DE - Germania 89
BR - Brasile 82
IN - India 74
CA - Canada 63
PH - Filippine 60
JP - Giappone 50
MX - Messico 46
FR - Francia 44
SE - Svezia 41
RU - Federazione Russa 40
TH - Thailandia 38
UA - Ucraina 29
KR - Corea 22
ID - Indonesia 19
NL - Olanda 19
SA - Arabia Saudita 19
ZA - Sudafrica 19
AR - Argentina 16
IQ - Iraq 16
TW - Taiwan 16
IE - Irlanda 15
EE - Estonia 14
TR - Turchia 14
JM - Giamaica 12
TG - Togo 12
AT - Austria 11
PK - Pakistan 11
CO - Colombia 9
CR - Costa Rica 9
EC - Ecuador 8
PL - Polonia 8
UZ - Uzbekistan 8
FI - Finlandia 7
VE - Venezuela 7
AU - Australia 6
ES - Italia 6
GT - Guatemala 6
PT - Portogallo 6
CL - Cile 5
EG - Egitto 5
HN - Honduras 5
JO - Giordania 5
KE - Kenya 5
MA - Marocco 5
PY - Paraguay 5
SC - Seychelles 5
SV - El Salvador 5
CI - Costa d'Avorio 4
DZ - Algeria 4
GH - Ghana 4
GR - Grecia 4
KZ - Kazakistan 4
NG - Nigeria 4
NI - Nicaragua 4
RO - Romania 4
CH - Svizzera 3
IL - Israele 3
MY - Malesia 3
RS - Serbia 3
TT - Trinidad e Tobago 3
BG - Bulgaria 2
BO - Bolivia 2
BS - Bahamas 2
CZ - Repubblica Ceca 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
GE - Georgia 2
IR - Iran 2
KW - Kuwait 2
LB - Libano 2
MM - Myanmar 2
OM - Oman 2
PE - Perù 2
PR - Porto Rico 2
SY - Repubblica araba siriana 2
UY - Uruguay 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AM - Armenia 1
BB - Barbados 1
BE - Belgio 1
BF - Burkina Faso 1
GY - Guiana 1
HU - Ungheria 1
KH - Cambogia 1
LK - Sri Lanka 1
LV - Lettonia 1
ME - Montenegro 1
MU - Mauritius 1
NO - Norvegia 1
PS - Palestinian Territory 1
QA - Qatar 1
Totale 6.231
Salva come PNG Salva come JPEG
Città #
Hanoi 234
Ho Chi Minh City 222
Singapore 218
Ashburn 208
San Jose 154
Southend 139
Santa Clara 136
Fairfield 113
New York 113
Hong Kong 81
Dong Ket 72
Los Angeles 72
Houston 62
Seattle 60
Wilmington 59
Woodbridge 53
Beijing 51
Bologna 51
Da Nang 42
Chandler 40
Chicago 40
Haiphong 40
Princeton 39
Cambridge 38
Milan 38
Dallas 35
Buffalo 34
Council Bluffs 34
Rome 34
Tokyo 32
Mexico City 28
Ann Arbor 25
Boardman 25
Nanjing 21
Florence 20
Frankfurt am Main 20
San Francisco 20
Naples 18
Phoenix 17
Westminster 17
Dublin 16
Lauterbourg 16
Padova 16
Bangkok 15
Berlin 14
Jacksonville 14
Toronto 13
Lomé 12
Quezon City 12
Shenyang 12
Atlanta 11
Hải Dương 11
Jinan 11
Las Vegas 11
Shanghai 11
Biên Hòa 10
Can Tho 10
Charlotte 10
Miami 10
Philadelphia 10
Turin 10
London 9
Manila 9
Jeddah 8
Saint Petersburg 8
Amsterdam 7
Des Moines 7
Nanchang 7
Napoli 7
Palermo 7
Pasadena 7
San Diego 7
San José 7
Columbus 6
Falls Church 6
Guatemala City 6
Kingston 6
Queens 6
Quận Ba 6
São Paulo 6
Tashkent 6
Washington 6
Amman 5
Baltimore 5
Bari 5
Bình Phước 5
Calgary 5
Changsha 5
Haikou 5
Hebei 5
Helsinki 5
Istanbul 5
Long Xuyen 5
Montreal 5
Nairobi 5
Orem 5
Portland 5
Redondo Beach 5
Rimini 5
Rio de Janeiro 5
Totale 3.244
Salva come PNG Salva come JPEG
Nome #
Gout, allopurinol intake and clinical outcomes in the hospitalized multimorbid elderly. 186
Shared topics on the experience of people with haemophilia living in the UK and the USA and the influence of individual and contextual variables: Results from the hero qualitative study 162
When healthcare professionals express themselves: results overview of the qualitative phase of the HERO initiative 153
Psychological interventions for people with hemophilia 152
Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis 150
Joint use of cardio-embolic and bleeding risk scores in elderly patients with atrial fibrillation 150
Objectives and methodology: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET) 143
Psychological interventions for people with hemophilia 140
AFFECTIVE COGNITIVE AND AFFECTIVE NON-COGNITIVE SOCIAL OBJECTS: A CASE STUDY OF SOCIAL REPRESENTATION OF HEAMOPHILIA FROM THE HERO PROJECT 131
Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis. 128
Risk factors for hospital readmission of elderly patients. 126
Residual venous obstruction, alone and in combination with D-dimer, as a risk factor for recurrence after anticoagulation withdrawal following a first idiopathic deep vein thrombosis in the prolong study. 123
null 121
Comparison of disease clusters in two elderly populations hospitalized in 2008 and 2010. 119
D-dimer testing to determine the duration of anticoagulation therapy. 119
Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis A patient-level meta-analysis 105
The process of construction and re-construction of the social representation of haemophilia: sensitive issues and affective-cognitive implications 102
null 73
Core GRADE 6: Presenting the evidence in summary of findings tables 65
Why Core GRADE is needed: Introduction to a new series in the BMJ 58
Development and evaluation of the population pharmacokinetic models for FVIII and FIX concentrates of the WAPPS-Hemo project 58
Non-severe haemophilia: Is it benign? – Insights from the PROBE study 53
Core GRADE 3: Rating certainty of evidence-assessing inconsistency 51
Attitudes and perceptions towards the use of artificial intelligence chatbots in medical journal peer review: A protocol for a large-scale, international cross-sectional survey 51
Attitudes and perceptions of biomedical journal editors in chief towards the use of artificial intelligence chatbots in the scholarly publishing process: a cross-sectional survey 50
Translating clinical questions by physicians into searchable queries: Analytical survey study 50
Treatment switch to nonacog beta pegol factor IX in hemophilia B: A Canadian cost-consequence analysis based on real-world factor IX consumption and clinical outcomes 50
A Global Cross‐Sectional Database Study of Low Dose FVIII SHL Prophylaxis in Haemophilia A 49
Kinetic Modeling for BT200 to Predict the Level of Plasma-Derived Coagulation Factor VIII in Humans 49
Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference? 49
Clinical application of Web Accessible Population Pharmacokinetic Service—Hemophilia (WAPPS-Hemo): Patterns of blood sampling and patient characteristics among clinician users 48
GRADE Guidance: Update on Developing Good Practice Statements in Guidelines 46
null 46
von Willebrand factor propeptide variants lead to impaired storage and ER retention in patient-derived endothelial colony-forming cells 45
Favorable Pharmacokinetic Characteristics of Extended-Half-Life Recombinant Factor VIII BAY 94-9027 Enable Robust Individual Profiling Using a Population Pharmacokinetic Approach 45
Reporting guideline for chatbot health advice studies: The CHART statement 45
Canadian Clinical Experience on Switching From Standard Half‐life Recombinant Factor VIII (rFVIII), Octocog Alfa, to Extended Half‐life rFVIII, Damoctocog Alfa Pegol, in Persons With Haemophilia A ≥ 12 Years Followed in a Comprehensive Haemophilia Care Program in Canada 44
Which actionable statements qualify as good practice statements In Covid-19 guidelines? A systematic appraisal 44
Attitudes and perceptions of medical researchers towards the use of artificial intelligence chatbots in the scientific process: an international cross-sectional survey 43
Knowledge translation strategies for sharing evidence-based health information with older adults and their caregivers: findings from a persona-scenario method 42
Benchmarking domain-specific pretrained language models to identify the best model for methodological rigor in clinical studies 41
The WFH Guidelines for the Management of Haemophilia: AAV Gene Therapy, 2025 41
COVID-19 coronavirus research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine 41
Country-level prediction of blood type distribution in hemophilia A in support of factor VIII consumption 39
Experimental evidences on the role of silica nanoparticles surface morphology on the loading, release and activity of three proteins 38
Core GRADE unpacked: a summary of recent innovations in complementary GRADE methodology 38
Core GRADE 5: rating certainty of evidence—assessing indirectness 37
Exploring the Impact of Laboratory Reagents on Pharmacokinetic Profiling 37
Risk Factors for the Development of Food Allergy in Infants and Children A Systematic Review and Meta-Analysis 37
Evaluation of the Burden of Bone Fractures in People Living With Haemophilia: A Registry‐Based Matched Cohort Study 37
American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing 36
A mixed-methods survey and focus group study to understand researcher and clinician preferences for a Journal Transparency Tool 36
Extended half-life factor VIII concentrates in adults with hemophilia A: Comparative pharmacokinetics of two products 36
The World Federation of Hemophilia Annual Global Survey 1999-2018 35
Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A 35
External qualification of the Web-Accessible Population Pharmacokinetic Service–Hemophilia (WAPPS-Hemo) models for octocog alfa using real patient data 34
Overall prognosis of preschool autism spectrum disorder diagnoses 34
Prevalence of selected bleeding and thrombotic events in persons with hemophilia versus the general population: A scoping review 34
florio HAEMO-A Digital Medical Device for Monitoring of Treatment, Symptoms and Physical Activities for People Living With Haemophilia 34
Core GRADE 2: Choosing the target of certainty rating and assessing imprecision 33
Developing a Two‐Sided Decision Box to Facilitate Shared Decision‐Making for Switching From Conventional to Pharmacokinetic‐Tailored Prophylaxis in Haemophilia 33
Reported prevalence of von Willebrand disease worldwide in relation to income classification 33
Core GRADE 1: Overview of the Core GRADE approach 33
ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura 33
Methodological considerations for investigating oral anticoagulation persistence in atrial fibrillation 32
GRADE concept paper 9: rationale and process for creating a GRADE Ontology 32
Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B 31
Comparative safety of drug therapies used in hemophilia A and B in Canada: a multi-center, retrospective study 30
Prescriber adherence to guidelines for chronic noncancer pain management with opioids: Systematic review and meta-analysis 30
Terminal half-life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database 30
Test–retest reliability of a mobile application of the patient reported outcomes burdens and experiences (PROBE) study 30
GRADE guidance 35: update on rating imprecision for assessing contextualized certainty of evidence and making decisions 30
Validating the “feasibility, acceptability, cost, and equity” instrument using stakeholder perceptions of feasibility, acceptability, cost, and equity in guideline implementation 29
Point of care ultrasound in haemophilia: Building a strong foundation for clinical implementation 29
How to write a guideline: A proposal for a manuscript template that supports the creation of trustworthy guidelines 28
Feasibility of Administering the Patient Reported Outcomes, Burdens and Experiences (PROBE) Questionnaire Through the Canadian Bleeding Disorders Registry (CBDR) and Comparison of Data From the Two Sources 28
The McMaster Health Information Research Unit: Over a Quarter-Century of Health Informatics Supporting Evidence-Based Medicine 27
GRADE Guidance 34: update on rating imprecision using a minimally contextualized approach 27
The World Federation of Hemophilia World Bleeding Disorders Registry: insights from the first 10,000 patients 27
Accuracy and Acceptability of Wrist-Wearable Activity-Tracking Devices: Systematic Review of the Literature 26
Protocol for a scoping review of outcomes in clinical studies of interventions for venous thromboembolism in adults 26
Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously untreated or minimally treated children with hemophilia A or B 26
Von Willebrand Disease: Gaining a global perspective 26
Switching to nonacog beta pegol in hemophilia B: Outcomes from a Canadian real-world, multicenter, retrospective study 26
Outcomes for studies assessing the efficacy of hemostatic therapies in persons with congenital bleeding disorders 25
Grading of recommendations, assessment, development and evaluations concept 7: issues and insights linking guideline recommendations to trustworthy essential medicine lists 25
Development and application of health outcome descriptors facilitated decision-making in the production of practice guidelines 25
World Federation of Hemophilia Gene Therapy Registry 25
Health utilities in adults with hemophilia A: A retrospective cohort study 25
Publisher preferences for a journal transparency tool: A modified three-round Delphi study 25
ISTH guidelines for treatment of thrombotic thrombocytopenic purpura 25
Comparison of single subject and population-based pharmacokinetics for optimizing prophylaxis with simoctocog alfa in patients with haemophilia A 25
Development of a Plasminogen Population PK model supporting prophylactic replacement therapy for Plasminogen deficient patients within the WAPPS‐Hemo platform 25
Evaluation of the sexual health in people living with hemophilia 24
Multicentre pharmacokinetic evaluation of rFVIII-Fc (efmoroctocog alfa) in a real life and comparison with non-extended half-life FVIII concentrates 24
Switching from standard to extended half-life FVIII prophylaxis in haemophilia A: Comparison of factor product use, bleed rates and pharmacokinetics 24
Association of body weight with efficacy and safety outcomes in phase III randomized controlled trials of direct oral anticoagulants: a systematic review and meta‐analysis 24
Deep learning to refine the identification of high-quality clinical research articles from the biomedical literature: Performance evaluation 23
A personalized limited sampling approach to better estimate terminal half-life of FVIII concentrates 23
A decision algorithm for assessing indirectness in core GRADE 23
Totale 5.289
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.533
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.533
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022292 41 13 11 10 30 23 8 24 12 17 45 58
2022/2023201 26 34 8 27 16 18 5 10 28 4 20 5
2023/202477 6 12 7 5 5 11 4 2 7 4 12 2
2024/2025310 19 62 15 20 90 19 17 3 6 9 3 47
2025/20264.782 33 32 53 29 64 36 105 82 1.718 1.100 883 647
2026/2027281 281 0 0 0 0 0 0 0 0 0 0 0
Totale 6.779